Which has grown faster, EDIT or MYGN?

Over the past five years, MYGN grew revenue faster — EDIT at a -10.34% CAGR versus MYGN at 9.70%.

How have EDIT and MYGN total returns compared?

Over the past 10 years, EDIT delivered -15.75% and MYGN delivered -14.20% annualized total return. Past performance doesn't predict future results.

Editas Medicine, Inc. (EDIT) vs Myriad Genetics, Inc. (MYGN)

A side-by-side comparison of Editas Medicine, Inc. and Myriad Genetics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

EDIT

Editas Medicine, Inc.

$427M

$2.79HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT

MYGN

Myriad Genetics, Inc.

$403M

$4.27HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT

Total return — EDIT vs MYGN

growth of $100 · dividends reinvested · last 10y

EDIT -81.4% (-15.5%/yr)MYGN -77.8% (-14.0%/yr)MYGN compounded faster over this window

EDIT MYGN

EDIT vs MYGN: by the numbers

•EDIT is the larger company ($427M vs $403M market cap).
•Both run net losses; MYGN's is the smaller (-13.96% vs -157.32% net margin).
•MYGN grew revenue faster over the past five years (9.70% vs -10.34% CAGR).

Metrics side by side

Valuation

Metric	EDIT	MYGN
P/S ratio	9.09	0.50
P/B ratio	4.06	1.33

Profitability

Metric	EDIT	MYGN
Gross margin	100.00%	68.83%
Operating margin	-245.15%	-12.22%
Net margin	-157.32%	-13.96%
ROE	-70.24%	-37.05%
ROIC	-48.61%	-19.13%

Growth (annualized)

Metric	EDIT	MYGN
Revenue CAGR (5Y)	-10.34%	9.70%
Total return CAGR (5Y)	-40.76%	-32.02%

Frequently asked

Which has grown faster, EDIT or MYGN?: Over the past five years, MYGN grew revenue faster — EDIT at a -10.34% CAGR versus MYGN at 9.70%.
How have EDIT and MYGN total returns compared?: Over the past 10 years, EDIT delivered -15.75% and MYGN delivered -14.20% annualized total return. Past performance doesn't predict future results.

Go deeper

Full EDIT analysis Full MYGN analysis Interactive comparison tool

Dig into the metrics

Editas Medicine ROE Myriad Genetics ROE Editas Medicine operating margin Myriad Genetics operating margin Editas Medicine revenue growth Myriad Genetics revenue growth Editas Medicine free cash flow Myriad Genetics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.